172 related articles for article (PubMed ID: 24521712)
1. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.
Carter YM; Kunnimalaiyaan S; Chen H; Gamblin TC; Kunnimalaiyaan M
Cancer Biol Ther; 2014 May; 15(5):510-5. PubMed ID: 24521712
[TBL] [Abstract][Full Text] [Related]
2. New methods to control neuroblastoma growth.
Dent P
Cancer Biol Ther; 2014 May; 15(5):481-2. PubMed ID: 24618834
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.
Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
HPB (Oxford); 2015 Sep; 17(9):770-6. PubMed ID: 26147011
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.
Kunnimalaiyaan S; Schwartz VK; Jackson IA; Clark Gamblin T; Kunnimalaiyaan M
BMC Cancer; 2018 May; 18(1):560. PubMed ID: 29751783
[TBL] [Abstract][Full Text] [Related]
5. MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype.
Chen JY; Cook MR; Pinchot SN; Kunnimalaiyaan M; Chen H
J Surg Res; 2010 Jan; 158(1):15-9. PubMed ID: 19765735
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of GSK-3β reverses the pro-apoptotic effect of proadifen (SKF-525A) in HT-29 colon adenocarcinoma cells.
Jendželovský R; Koval J; Mikeš J; Papčová Z; Plšíková J; Fedoročko P
Toxicol In Vitro; 2012 Sep; 26(6):775-82. PubMed ID: 22683934
[TBL] [Abstract][Full Text] [Related]
7. Potential Role of Glycogen Synthase Kinase-3β in Regulation of Myocardin Activity in Human Vascular Smooth Muscle Cells.
Zhou YX; Shi Z; Singh P; Yin H; Yu YN; Li L; Walsh MP; Gui Y; Zheng XL
J Cell Physiol; 2016 Feb; 231(2):393-402. PubMed ID: 26129946
[TBL] [Abstract][Full Text] [Related]
8. GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line.
Dickey A; Schleicher S; Leahy K; Hu R; Hallahan D; Thotala DK
J Neurooncol; 2011 Aug; 104(1):145-53. PubMed ID: 21161565
[TBL] [Abstract][Full Text] [Related]
9. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Ban JO; Oh JH; Son SM; Won D; Song HS; Han SB; Moon DC; Kang KW; Song MJ; Hong JT
Cancer Biol Ther; 2011 Aug; 12(4):288-96. PubMed ID: 21613824
[TBL] [Abstract][Full Text] [Related]
11. GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
Aristizabal Prada ET; Weis C; Orth M; Lauseker M; Spöttl G; Maurer J; Grabowski P; Grossman A; Auernhammer CJ; Nölting S
Neuroendocrinology; 2018; 106(4):335-351. PubMed ID: 28968593
[TBL] [Abstract][Full Text] [Related]
12. AR-A014418 as a glycogen synthase kinase-3 inhibitor: anti-apoptotic and therapeutic potential in experimental spinal cord injury.
Tunçdemir M; Yıldırım A; Karaoğlan A; Akdemir O; Oztürk M
Neurocirugia (Astur); 2013; 24(1):22-32. PubMed ID: 23116585
[TBL] [Abstract][Full Text] [Related]
13. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.
Bhat R; Xue Y; Berg S; Hellberg S; Ormö M; Nilsson Y; Radesäter AC; Jerning E; Markgren PO; Borgegård T; Nylöf M; Giménez-Cassina A; Hernández F; Lucas JJ; Díaz-Nido J; Avila J
J Biol Chem; 2003 Nov; 278(46):45937-45. PubMed ID: 12928438
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
[TBL] [Abstract][Full Text] [Related]
15. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.
Ougolkov AV; Fernandez-Zapico ME; Bilim VN; Smyrk TC; Chari ST; Billadeau DD
Clin Cancer Res; 2006 Sep; 12(17):5074-81. PubMed ID: 16951223
[TBL] [Abstract][Full Text] [Related]
16. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.
Madhunapantula SV; Sharma A; Gowda R; Robertson GP
Pigment Cell Melanoma Res; 2013 Nov; 26(6):886-99. PubMed ID: 24034838
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells.
Yoshino Y; Ishioka C
Sci Rep; 2015 Aug; 5():13249. PubMed ID: 26292722
[TBL] [Abstract][Full Text] [Related]
18. GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells.
Lee YC; Shi YJ; Wang LJ; Chiou JT; Huang CH; Chang LS
J Cell Physiol; 2021 Jan; 236(1):570-586. PubMed ID: 32572959
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies.
Vasdev N; Garcia A; Stableford WT; Young AB; Meyer JH; Houle S; Wilson AA
Bioorg Med Chem Lett; 2005 Dec; 15(23):5270-3. PubMed ID: 16202587
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells.
Yeste-Velasco M; Folch J; Trullàs R; Abad MA; Enguita M; Pallàs M; Camins A
Neuropharmacology; 2007 Aug; 53(2):295-307. PubMed ID: 17612578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
